A retrospective study of ultrahigh-risk (Mayo 2004 stage IIIb) AL amyloidosis and identification of predictors related to extremely early death.

Considering the adverse outcomes of these patients, Mayo 2004 stage IIIb patients were not included in most clinical trials. (B) Survival of Mayo 2004 stage IIIb AL amyloidosis patients categorized by treatment (bortezomib-based regimen, immunomodulator (IMID) or melphalan combination and supportive care group). Among patients with available clinical assessments ( I n i = 69), the overall response rate was 52.2% ( I n i = 36), with 22 patients (31.9%) achieving a complete response (CR) and 8 patients (11.6%) achieving a very good partial response (VGPR). [Extracted from the article]